Background: A high prevalence of cannabis use disorder has been reported in subjects suffering from schizophrenia, fueling intense debate about whether schizophrenia with pre-onset cannabis use disorder may be a…
Condition: Schizophrenia
Activity of cannabis in relation to its delta’-trans-tetrahydro-cannabinol content
Conditions have been worked out for a reliable estimation of the cataleptic activity of delta’-trans-tetrahydrocannabinol (THC) after oral administration to mice, using the ring test over a period of 6…
Cannabidiol in Humans—The Quest for Therapeutic Targets
Cannabidiol (CBD), a major phytocannabinoid constituent of cannabis, is attracting growing attention in medicine for its anxiolytic, antipsychotic, antiemetic and anti-inflammatory properties. However, up to this point, a comprehensive literature…
Cannabidiol Reverses MK-801-Induced Disruption of Prepulse Inhibition in Mice
Cannabidiol, a nonpsychoactive constituent of the Cannabis sativa plant, has been reported to act as an agonist of the vanilloid 1 channel in the transient receptor potential family (TRPV1) and…
Cannabinoid–Dopamine Interaction in the Pathophysiology and Treatment of CNS Disorders
Endocannabinoids and their receptors, mainly the CB1 receptor type, function as a retrograde signaling system in many synapses within the CNS, particularly in GABAergic and glutamatergic synapses. They also play…
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Cannabidiol is a component of marijuana that does not activate cannabinoid receptors, but moderately inhibits the degradation of the endocannabinoid anandamide. We previously reported that an elevation of anandamide levels…
Cortical GAD67 deficiency results in lower cannabinoid 1 receptor mRNA expression: Implications for schizophrenia
Abstract Background Levels of cannabinoid 1 receptor (CB1R) mRNA and protein, which are expressed most heavily in the cholecystokinin class of GABA neurons, are lower in the dorsolateral prefrontal cortex…
Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis
Cannabis contains various cannabinoids, two of which have almost opposing actions: D9-tetrahydrocannabinol (D9-THC) is psychotomimetic, whereas cannabidiol (CBD) has antipsychotic effects. Hair samples were analysed to examine levels of D9-THC…
The Development of Cannabidiol as a Psychiatric Therapeutic: A Review of Its Antipsychotic Efficacy and Possible Underlying Pharmacodynamic Mechanisms
Cannabidiol (CBD), a once-considered inert cannabis constituent, is one of two primary constituents of cannabis, alongside delta-9-tetrahydrocannabinol (∆9-THC/THC). In the last 30 years, CBD has become implicated with a range…